Altimmune

Biotech

Altimmune (ALT) Stock Soars 27%: Phase 2 Data on Obesity Drug Ignites Market Optimism

June 24, 2024
0
Altimmune scientist working working with test tubes in a lab.

In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning,…

Read More »
Back to top button